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Recent studies have revealed an abnormality in the peripheral metabolism of thyroxine in patients with active untreated Graves' disease (1) . In such patients, an abnormally large fraction of the extrathyroidal pool of thyroxine is degraded daily.
Other authors have also observed an accelerated fractional turnover of thyroxine in patients with untreated Graves' disease (2, 3) and have postulated that the rate of turnover of the hormone might be a function of its concentration in the blood (2) . Alternatively, accelerated turnover of thyroxine might merely reflect the general speeding of metabolic processes which occurs during the hyperthyroid state. The present studies were designed to differentiate between these and other possibilities. Rates of turnover of thyroxine have been assessed in patients in whom the thyrotoxicity had been corrected by appropriate therapy, as well as in nonthyrotoxic subjects who were made hypermetabolic by the administration of thyroid hormone. A preliminary report of the data obtained has been published in abstract form (4) . It has been shown that the induction of thyrotoxicosis medicamentosa does result in an augmentation of the fractional rate of turnover of thyroxine. However, it has also been demonstrated that accelerated fractional turnover of thyroxine frequently persists in patients with Graves' disease, despite prolonged correction of the hypermetabolic state, and despite reduction of the protein-bound iodine (PBI) to normal or subnormal values. It is apparent, therefore, that the increase in the fractional rate of thyroxine turnover which occurs in patients with Graves' disease cannot be entirely ascribed to either the concentration of circulating thyroid hormone or the immediate metabolic status of the patient.
PATIENT MATERIAL (Table I) . Forty determinations of the rate of turnover of thyroxine were made in 23 patients with treated Graves' disease. With but 7 exceptions, all patients had been followed continuously by the authors since the diagnosis of Graves' disease had first been made.
Twenty-two tests were performed in 15 patients who were being treated with propylthiouracil or methylmercaptoimidazole. Duration of symptomatic remission ranged from 2 to 26 months and averaged 12 months. In four instances, tests were performed following 1 month in which antithyroid medication was supplemented by the administration of Lugol's solution, 10 drops, three times daily. Seven additional tests were performed in six of these subjects from 4 to 14 months following withdrawal of propylthiouracil. In these subjects, symptomatic remission had been effected for 17 to 39 months.
Nine tests were performed in seven subjects who had been treated by subtotal thyroidectomy from 7 months to 10 years earlier. One of these patients (No. 12) had previously been studied while receiving antithyroid therapy.
Measurements of the rate of turnover of thyroxine were also made in one patient treated with Lugol's solution and another patient treated with radioactive iodine, five and six years earlier, respectively.
Values were compared with those obtained in normal subjects and in patients with untreated myxedema or thyrotoxicosis. Previously reported data for subj ects in these categories (1) have been supplemented by the study of additional patients.
In order to ascertain the reproducibility of the measurement, two determinations of thyroxine turnover were secured in six normal subjects at intervals of three to 1603 eight months. Values of thyroxine half-time did not vary by more than 0.3 day.
Methods
Thyroxine turnover. The distribution and rate of turnover of thyroxine were measured by a method described previously (1) . Briefly, thyroxine (4 to 5 gsg.), labeled with 30 luc. of I3 was injected intravenously and total daily urinary collections as well as daily specimens of plasma were obtained for the ensuing 9 to 12 days. The virtual volume of distribution of thyroxine was calculated daily. After complete equilibration of the injected isotope, as evidenced by constancy of its volume of distribution, the thyroxine half-time was estimated from the slope of the curve depicting the concentration of the radioactivity in the serum. The fractional rate of turnover of thyroxine was calculated as the quotient, 0.693/half-time (day). Daily degradation of hormonal iodine (daily degradation rate) was calculated as the product, PBI (,jg. per L.) X volume of distribution (liters) X fractional turnover rate (per cent per day).
In several instances, in order to avoid economic hardship to the patient, studies were performed on an outpatient basis. In such cases, urinary collections were not made. Fractional rates of turnover of thyroxine were estimated from the slope of the time-concentration curve of radiothyroxine in plasma, employing only data obtained subsequent to the first 48 hours following injection of the tracer. The volume of distribution of thyroxine was estimated, using the isotope dilution principle, by extrapolation of this portion of the curve to zero-time (the time of injection).
It had previously been noted, in patients with untreated Graves' disease, that accelerated fractional turnover of thyroxine rapidly liberated radioiodide which was quickly accumulated by the thyroid gland and released as labeled hormone. This recycled moiety produced an apparent retardation of the rate of disappearance from the plasma of the initially injected radiothyroxine (1) . This difficulty could be circumvented if thyroidal reutilization of liberated radioiodide were completely inhibited by antithyroid drugs. Accordingly, all patients in the present studies were given 30 mg. of methylmercaptoimidazole every six hours during the testing procedure. By direct counting over the neck, this dosage of drug was shown to prevent appreciable thyroidal accumulation of the radioiodine liberated by the degradation of labeled thyroxine.
In all instances, determination of the 24 hour thyroidal percentage accumulation of a tracer dose of radioiodine as well as measurements of basal metabolic rate were made within the week prior to the determination of the thyroxine turnover rate. In patients receiving antithyroid drugs, medication was continued in its usual dosage during the measurement of thyroidal radioiodine uptake. Tracer doses of inorganic iodide were suffi-8 Obtained from Abbott Laboratories, Oak Ridge, Tenn. ciently small (3 uc.) so that any accumulated 131 released during the subsequent turnover study would not obscure the true rate of disappearance of injected radioactive thyroxine from the plasma.
Thyroxine-binding protein. In eight patients who displayed persistently accelerated turnover of thyroxine, the capacity of the serum's inter-alpha migrating thyroxine-binding protein (TBP) to bind thyroxine was assessed by techniques described in detail elsewhere (5) . Sera from these and from normal control subjects were enriched with stable and with I'-labeled thyroxine in amounts sufficient to achieve four standard concentrations of added thyroxine over the range from 10 to 160 ,ug.
per cent Sera were then subjected to electrophoresis in filter paper, using veronal buffer, pH 8.6, ionic strength 0.05. The distribution of radioactivity in the individual electrophoretograms was ascertained in an automatically recording strip-scanner. Scanning patterns were then traced onto hard paper of uniform thickness. The weight of the tracing of the radioactive components associated with albumin and with TBP were determined on an analytical balance, and were expressed as a percentage of the total weight of the tracing. Values from normal subjects and from patients with treated Graves' disease were compared.
Suppression of thyroidal uptake of Ia. On 30 occasions in 21 patients, the ability of exogenous thyroid hormone to suppress thyroidal accumulation of radioiodine was assessed. Three patients were studied before and after the oral administration of 75 ,ug. of triiodothyronine daily for three weeks. Eighteen patients received desiccated thyroid (U.S.P.) according to the following dosage schedule: following three weeks of an initial dosage of 2 or 3 gr. daily, thyroidal uptake was repeated. If suppression had not been achieved, the dosage was increased by 2 gr. daily during each two week period until suppression was achieved or until a dosage of 8 or 9 gr. daily had been employed. In one patient (No. 13), this regimen was discontinued at a dosage of 5 gr. daily because of severe symptoms of thyrotoxicity. Suppression was considered to have occurred if the 24 hour thyroidal uptake of radioiodine was decreased either to less than 10 per cent of the administered dose or to less than half of its initial value.
In six of the patients in whom suppression was achieved, thyroidal uptakes were allowed to return to control values. During the ensuing three to four weeks, patients were given quantities of inorganic iodine equal to the iodine content of the suppressive dose of desiccated thyroid. Thyroidal uptake was then re-evaluated.
Induction of thyrotoxicosis medicamentosa (Table II) . The effect of artificially induced thyrotoxicosis on the peripheral turnover of thyroxine was assessed in four patients. One patient with nontoxic nodular goiter was given 10 gr. of desiccated thyroid daily. One patient with treated Graves' disease, one with nontoxic goiter, and one patient with primary amenorrhea were given 200 /Ag. of triiodothyronine daily. Studies of the peripheral turnover of thyroxine were performed before and at the end of a 60 day treatment period. § Values in patients receiving triiodothyronine, indicated in parentheses, are presumed to be inaccurate, since neither the rate of turnover of triiodothyronine nor its percentage contribution to the PBI were determined.
In addition, studies of thyroxine turnover were performed in two patients with treated Graves' disease and one patient with nontoxic nodular goiter before and after a 60 day treatment period with 500 ug. daily of diiodotyrosine.
Chemical analysis and radioactive assay. Concentrations of protein-bound iodine (PBI) were determined by the method of Barker, Humphrey and Soley in sera obtained from each patient at the beginning and the conclusion of the thyroxine turnover study (6) .4 Assays for radioactivity in blood, urine, and thyroid gland were performed as previously described (1) . RESULTS (TABLE I) Patients studied during therapy with antithyroid drugs In 22 tests performed in 15 patients, thyroxine half-time averaged 4.8 ± 0.8 days (mean + standard deviation), a value significantly different from the normal of 6.8 + 0.5 (p <0.001). Only four subjects (Nos. 1, 8, 9, 13) exhibited half-times within the normal range ( Figure 1 ). Duration of remission averaged 12 months in both these subjects and in the subjects with abnormally rapid turnover of thyroxine. Of per day, despite the reduction in the concentration of circulating thyroid hormone.
Values for the 24 hour thyroidal uptake of I131 averaged 64 + 16 per cent for the entire group, and only four values of less than 50 per cent were noted. The latter value is considered to be the upper limit of normal in this laboratory. Thyroidal uptakes in the seven patients with subnormal PBI's averaged 68 per cent. In the four instances in which it was assessed, no demonstrable discharge of thyroidal radioactivity followed the oral administration of 1.0 Gm. of potassium thiocyanate.
Suppression of thyroidal uptake by exogenous hormone was assessed 17 times in 15 patients, and was achieved in 13 instances. In 3 of the 4 instances in which suppression was not achieved, subnormal values for thyroxine half-time were present. Except in 1 patient (No. 3) in whom 5 gr. was required, the daily dose of desiccated thyroid necessary to effectuate suppression ranged between 2 and 4 gr. In cluding normal individuals and patients with myxedema or nontoxic goiter, have been given comparable doses of antithyroid drug during determination of thyroxine degradation rate. In 21 normal subjects studied on this regimen, no difference in the rate of turnover of thyroxine could be discerned from values previously reported in 9 normal subjects studied without thyroidal blockade (1) . Thus the effect of methyl-mercaptoimidazole, if any, must be selectively exerted in the population with treated Graves' disease. One pharmacological factor, however, requires further inquiry. In three of four patients studied with and without supplementation of antithyroid medication by Lugol's solution, thyroxine half-times were longer when iodine was concomitantly administered. These observations are perhaps correlated with the reported inhibition by iodide of the deiodination of thyroxine in vitro (8, 9). Although acute administration of iodides has not altered the half-time of thyroxine in nonthyrotoxic subjects (3), studies are now in progress to ascertain the effects, if any, of iodide on the turnover of thyroxine in patients with treated Graves' disease.
In the present studies, evaluation of the duration of accelerated turnover of thyroxine is rendered difficult by the variation in the mode of therapy employed. Thus, the majority of patients studied more than 3 years after treatment had undergone subtotal thyroidectomy, and displayed a normal rate of thyroxine turnover. On the other hand, the majority of patients studied during the first few years after onset of treatment had been treated with antithyroid drugs and displayed an abnormally rapid rate of thyroxine turnover. Despite the preponderance of abnormal values in patients treated with antithyroid drugs, the data do not support the supposition that the abnormally rapid turnover of thyroxine was somehow conditioned by these agents. Four of six patients continued to demonstrate the abnormality during sustained remission following cessation of antithyroid therapy, and abnormal values were found in the two patients treated with stable or radioactive iodine. Furthermore, among patients treated surgically, abnormally rapid turnover of thyroxine was observed in those studies performed less than three years after operation. These data suggest that time, rather than mode of therapy, is the more important variable with regard to restoration of normal values.
Although the fractional turnover of thyroxine was abnormally rapid in the present group of patients with treated Graves' disease, it was nevertheless significantly (p < 0.001) slower than that found in patients with active thyrotoxicity (mean half-time 3.9 + 1.1 days, based on values obtained in 22 patients). In addition, in five of six patients studied prior to and during treatment, a reduction in the fractional turnover rate was noted after restoration of the eumetabolic state. Finally, the present studies have indicated that thyrotoxicosis medicamentosa can increase the fractional turnover of thyroxine. Thus, it seems likely that a portion of the acceleration of thyroxine turnover noted in patients with untreated Graves' disease results directly from the thyrotoxicosis or some concomitant thereof. However, the residual abnormality in the metabolism of thyroxine, noted in many patients in the present study, remained to be explained. No correlation was found between the presence or absence of increased fractional turnover of thyroxine and the age of the patient, or the presence of exophthalmos or of other associated endocrine or constitutional abnormalities. An explanation was further sought among those factors which have been suggested as possible determinants of the peripheral turnover of thyroxine. These have been extensively considered in an earlier communication (10) , and will be considered here in relation to the present findings.
In serum, thyroxine is bound to specific transport proteins, one of which migrates during paper electrophoresis at pH 8.6 in the zone between the a, and a2 globulins (11) . This moiety has been termed the thyroxine-binding protein of plasma (TBP). Recently another highly potent thyroxine-binding protein has been noted in serum, having an anodal electrophoretic mobility greater than that of albumin (pre-albumin) (12) . It has been suggested that the distribution and rate of turnover of thyroxine might be governed by the metabolism of the proteins to which it is bound, and it was initially suggested that the accelerated turnover of proteins and other metabolites which occurs in patients with Graves' disease might lead to acceleration of the turnover of the hormone (1) . Although highly purified preparations of TBP and pre-albumin are now available (13), it has not as yet been possible to ascertain whether the turnover of these proteins remains abnormally rapid in patients with treated Graves' disease. In any event, accelerated turnover of protein resulting from hypermetabolism, per se, would seem to be excluded as a contributory factor in the treated patient, who may continue to demonstrate rapid turnover of thyroxine despite reduction of the metabolic rate to normal or subnormal values.
Riggs (14), as well as Berson and Yalow (2), have suggested that the quantity of thyroxine degraded daily might vary linearly with the square of the PBI. No explanation for this relationship was apparent. More recently, however, Robbins and Rall have offered the following suggestion (15) . These authors have hypothesized that in the plasma, thyroxine exists in equilibrium between the protein-bound and the free or unbound state. According to their calculations, values of free thyroxine vary inversely with the thyroxinebinding capacity of TBP and directly with the total concentration of hormone in the plasma. It was calculated that as the PBI increased, a progressively greater fraction of the plasma's hormone was present in the free state. Inspection of their data reveals that the calculated concentration of free thyroxine varies roughly with the square of the PBI. It is not surprising, therefore, that, employing the data of Berson and Yalow, Robbins and Rall found a linear relationship between the daily degradation of hormone and the concentration of free thyroxine.
Implicit in these considerations is the conclusion that the fractional rate of turnover of the total plasma hormone (the function measured in the present study) must vary with the concentration of free thyroxine as conditioned by a) the total concentration of hormone and b) the binding activity of TBP. In the present study, however, abnormally rapid fractional turnover of thyroxine has been found in patients whose PBI's were in the normal or the myxedematous range. Furthermore, since the sera of such patients demonstrated normal binding activity of TBP, calculated values of free thyroxine were normal or decreased. Thus, though the foregoing general relationships concerning thyroxine turnover may pertain in subjects with treated Graves' disease, they must at least be quantitatively altered, and the operation of other factors must be invoked.
Additional evidence in this regard is provided by the present patients made hypermetabolic with triiodotlyronine. In these patients, PBI diminished and the binding capacity of TBP was unchanged. Here, too, calculated concentrations of free thyroxine were diminished, but the fractional rate of turnover of thyroxine was increased.
It is thus apparent that quantitative alterations in the interaction between thyroxine and TBP cannot account for the increased fractional rate of turnover of thyroxine found in some patients with treated Graves' disease. The role of interactions between thyroxine and pre-albumin has not as yet been evaluated. Preliminary studies indicate that the thyroxine-binding capacity of pre-albumin is markedly diminished during active thyrotoxicosis. Since binding of thyroxine by pre-albumin appears to be a critical determinant of the cellular uptake of thyroxine in in vitra systems, especially at concentrations of hormone in the thyrotoxic range (13), the reported increase in the cellular uptake of thyroxine in vitro from the sera of thyrotoxic patients (16, 17) may be merely a manifestation of altered binding by prealbumin. Unfortunately, few data are available concerning cellular uptake of thyroxine from the serum of patients with treated Graves' disease, nor has it been possible as yet to assess the thyroxine-binding capacity of pre-albumin in a significant number of patients in this category.
Thus, the accelerated turnover of thyroxine found in some patients with treated Graves' disease cannot presently be correlated with any of the extracellular factors which have previously been suggested as possible determinants of the rate of turnover of the hormone. Attention may then turn to the possible role of factors within the cell itself. As has been suggested elsewhere (10) (19) . A similar sequence could occur in patients with active Graves' disease, and could be responsible, at least in part, for the accelerated turnover of thyroxine found in untreated patients. However, currently available data provide no basis for prediction of how long such adaptive increases in the deiodination of thyroxine might persist following alleviation of the hyperthyroxinosis. Persistence for as long as five or six years, the duration of the most persistent abnormalities in turnover noted in the present study, seems highly unlikely. The present data further indicate that if adaptive increases in deiodination do occur, they must be relatively substrate specific, since administration of large quantities of diiodotyrosine for periods of two months failed to alter the rate of turnover of thyroxine. The acceleration of thyroxine turnover found in patients made hypermetabolic with triiodothyronine might be construed as indicating that the two hormones share common deiodinating pathways. Alternatively, it seems possible that in these patients, as in rats given large doses of thyroxine, acceleration of hormonal degradation resulted from hypermetabolism, per se.
Thus, it is difficult to ascribe the increased fractional turnover of thyroxine found in some patients with treated Graves' disease to any of the several mechanisms which have already been suggested as possible regulators of the peripheral turnover of the hormone. However, other possibilities remain to be considered. Among these, consideration must be given to the thyroid gland itself.
In the present series, many, though not all of the patients who demonstrated abnormally large fractional rates of turnover of thyroxine also displayed 24 hour thyroidal uptakes of I131 well above the normal range. This was most commonly found in patients receiving antithyroid drugs. Administration of small quantities of iodine failed to diminish the increased uptakes, indicating that iodine deficiency was not responsible for the augmentation of uptake. In the several instances in which KSCN was administered, only a small fraction of the accumulated iodine could be discharged from the gland. Thus, it may be concluded that despite the antithyroid drugs, large quantities of iodine were being incorporated into organic moieties. Moreover, by direct counting over the neck, the rate of release of iodine from the thyroid gland of these patients was found to be rapid. Therefore, these organic moieties were being lost from the gland at a rapid rate. Measurements of protein-bound radioiodine in the plasma were not made. It is thus not possible to be certain whether the rapid disappearance of radioactivity from the gland represented intrathyroidal deiodination or secretion into the circulation. However, the normal values for PBI and BMR which were observed in these instances would suggest that if such material were indeed reaching the circulation, it was rapidly removed and had little calorigenic potency. (23) .
Another abnormality of iodine metabolism has been thought to reflect activity of the morbid process in Graves' disease. This is the failure of exogenous thyroid hormone, even in large doses, to suppress the thyroidal uptake of radioactive iodine (24, 25) . This abnormality, like the increased fractional turnover of thyroxine peripherally which has been described above, has been reported by Werner to persist for long periods after alleviation of active thyrotoxicity (26) . Moreover, like the abnormality of peripheral turnover, it frequently abates several years after treatment. In the present studies, no correlation was found between the presence or absence of thyroidal suppression by exogenous hormone and the presence of accelerated fractional turnover of thyroxine. The present data indicate that thyroidal suppression can commonly be achieved while patients are receiving antithyroid therapy. In patients treated by other means, and in patients observed following cessation of antithyroid therapy, the incidence of resistance to suppression in the present series seems less than that reported by Werner (26) , and more consistent with the data of Morgans, Oldham and Trotter (27) . It seems quite clear, at any rate, that the currently described abnormality is not of sufficient magnitude to account for resistance to suppression by large doses of exogenous hormone, based on increased disposal of the administered material. The precise relationship of the two abnormalities to each other and to the underlying pathogenesis of Graves' disease remains to be resolved in the future. 2. Among these patients, many displayed a persistence of increased fractional rate of turnover of the hormone in peripheral tissues for long periods after induction of symptomatic remission.
3. Although induction of thyrotoxicosis medicamentosa by the administration of either desiccated thyroid or triiodothyronine has been shown to increase the fractional rate of turnover of thyroxine, hypermetabolism, per se, cannot account for the increase noted in the patients with treated Graves' disease.
4. Analysis of several other factors which might influence the peripheral turnover of thyroxine has failed to reveal the cause of the abnormality in these patients.
